



Breast Cancer: New Diagnostic and Therapeutic Approaches

Guest Editors:

Dr. Erika Bandini

Biosciences Laboratory, IRCCS
Istituto Romagnolo per lo Studio
dei Tumori (IRST) “Dino
Amadori”, Meldola, Italy

Dr. Tania Rossi

IRCCS Istituto Scientifico per la
Cura dei Tumori “Dino Amadori”
IRST, Meldola, Italy

Dr. Sara Bravaccini

IRCCS Istituto Romagnolo per lo
Studio dei Tumori (IRST) “Dino
Amadori”, 47014 Meldola, Italy

Deadline for manuscript
submissions:

31 January 2025

Message from the Guest Editors

As the most diagnosed form of cancer worldwide, breast cancer (BC) represents a major health issue. In recent decades, researchers have intensively exploited next-generation sequencing (NGS) approaches to discover new actionable targets of breast tumor specimens, leading to the development of new therapy regimens (i.e., CDK4/6 inhibitors, PIK3CA inhibitors, etc.). More recently, novel approaches have been developed to improve cancer molecular characterization at epigenetic, transcriptomic, genetic and genomic levels. Moreover, the investigation of analytes retrievable in the peripheral blood (i.e., circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), etc.) has demonstrated an unprecedented potential to obtain further information concerning the core tumor. The topics of interest for this Special Issue can include, but are not limited to, the following:

- Prognostic and predictive biomarkers of breast cancer;
- Novel approaches to improve breast cancer characterization;
- Liquid biopsy in breast cancer;
- Genetic alterations in breast cancer





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)